TherapeuticsMD Announces 2014 Investor Day

TherapeuticsMD, Inc. (NYSE MKT: TXMD) announced today that it will host its 2014 Investor Day on Monday, June 16, 2014, beginning at 11:30 a.m. EDT at the InterContinental Barclay New York in New York City.

The event will feature a panel of prominent Clinical Key Opinion Leaders, Compounding Market Experts, former FDA Directors, and Legislative and Women’s Health Experts.

For more information and to confirm your attendance, contact Lisa Wilson by phone at 917-543-9932, by e-mail at lwilson@insitecony.com or on the home page of the Company's website at www.TherapeuticsMD.com.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is a women’s healthcare company focused on developing and commercializing products targeted exclusively for women. We are developing advanced hormone therapy pharmaceutical products based on novel technologies that enable delivery of bioidentical hormones through a variety of dosage forms and administration routes. We also manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD ® and BocaGreenMD ® brands. More information is available at the following websites: www.therapeuticsmd.com, www.vitamedmd.com, www.vitamedmdrx.com, and www.bocagreenmd.com.

Copyright Business Wire 2010

If you liked this article you might like

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More

Analysts' Actions -- Costco, J.C. Penney, Cisco, TherapeuticsMD and More

TherapeuticsMD Rejected by FDA, Delay Could Be Fatal

TherapeuticsMD Rejected by FDA, Delay Could Be Fatal

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

Penn National Gaming, Wynn Resorts: 'Mad Money' Lightning Round

Penn National Gaming, Wynn Resorts: 'Mad Money' Lightning Round

Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)

Valuation Is in the Eye of the Buyer: Cramer's 'Mad Money' Recap (Tuesday 4/4/17)